4d Molecular Therapeutics, Inc. income statement

In fiscal 2025, 4d Molecular Therapeutics, Inc. reported revenue of $85.2m, up 230194.6% on the year before, operating income of −$160m (a -187.2% margin) and net income of −$140m, or −$2.42 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

4d Molecular Therapeutics, Inc.: income statement, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	7	14	18	3	21	0	85	92
Research and development	39	53	61	80	97	141	196	240
General and administrative	14	17	28	33	36	47	49	49
Operating income	−51	−57	−71	−110	−113	−188	−160	−197
Income tax	—	0	0	0	0	0	0	0
Net income	−49	−57	−71	−107	−101	−161	−140	−179
Diluted EPS	−$9.59	−$8.82	−$2.57	−$3.32	−$2.58	−$2.98	−$2.42	−$2.77
Diluted shares (average)	5m	6m	28m	32m	39m	54m	58m	65m
EBITDA	−50	−55	−70	−108	−109	−183	−155	−192

US$ millions unless shown otherwise. Fiscal quarters.

4d Molecular Therapeutics, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	0	0	0	0	0	85	3	4
Research and development	38	43	41	48	49	58	65	68
General and administrative	13	13	13	12	12	13	12	13
Operating income	−51	−56	−54	−59	−61	15	−74	−77
Income tax	0	0	0	0	0	0	0	0
Net income	−44	−50	−48	−55	−57	19	−69	−73
Diluted EPS	−$0.79	−$0.90	−$0.86	−$0.98	−$1.01	$0.43	−$1.01	−$1.04
EBITDA	−50	−55	−53	−58	−60	16	−72	−76

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: FDMT vs VSTM AGIO vs FDMT FDMT vs SEPN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from 4d Molecular Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to 4d Molecular Therapeutics, Inc.